Warning: Undefined array key "article" in /home/askat/askat-inc.com/public_html/wp-content/themes/askat/single-news.php on line 27
EP4 Antagonist AAT-007 Clinical Study in Oncology Initiated in the People's Republic of China|News | AskAt, Inc.

nemu

HOME > NEWS

NEWS

EP4 Antagonist AAT-007 Clinical Study in Oncology Initiated in the People's Republic of China

2019/06/05

Ningbo NewBay Medical Technology Co., Ltd. (Headquarters in Ningbo, China, CEO: Zhenhai Shen; NewBay), announced that NewBay initiated a Phase I clinical study of the EP4 antagonist AAT-007 (generic name: grapiprant) in the People’s Republic of China (China) on June 4, 2019.  NewBay is a subsidiary of Ningbo Tai Kang Medical Technology Co., Ltd. (Tai Kang) which licensed AT-007 from AskAt Inc. for cancer therapy in China.  This is the first clinical trial of AAT-007 in China targeting cancer. AskAt will receive a milestone payment from Tai Kang in conjunction with the initiation of the study.

PAGE TOP

Menu